TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04553991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided QL block
Description: 20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided TAP block
Description: 20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
Study: NCT02173652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356, high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356, low dose
Study: NCT02946684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Adjuvant therapy to recFSH during ovarian stimulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study: NCT01741467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: Dexcom Seven+
Study: NCT03479931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without placement of a catheter
Description: Elective cesarean section without preoperative placement of a urinary catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With placement of a catheter
Description: Elective cesarean section with preoperative placement of a urinary catheter.
Study: NCT02948790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuristim
Description: Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implant
Description: Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
Study: NCT02450526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study: NCT02566707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: HIV therapy will be adapted: atazanavir 400mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: HIV therapy will be adapted: dolutegravir 50mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: HIV therapy will be adapted: lamivudine 300mg QD
Study: NCT01112644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone naloxone prolonged release tablets (OXN PR)
Description: Different daily doses; intake every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone naloxone prolonged release tablets (OXN PR)
Description: Different daily doses; intake every 12 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA)
Description: Different daily doses; intake every 12 hours
Study: NCT04596280

Intervention type: PROCEDURE
Intervention: Colonic Resection
Description: Resection of the colonic tract which has been interested by the acute diverticulitis
Study: NCT00011713

Intervention type: OTHER
Intervention: Completion questionnaires/providing biological samples
Description: Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
Study: NCT03106194

Intervention type: OTHER
Group type: OTHER
Intervention: case management
Study: NCT00809458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
Study: NCT00950079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: 0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
Study: NCT00084929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Colonography
Description: CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
Study: NCT04399512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical root canal treatment
Description: Nonsurgical root canal treatment will be given

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical root canal treatment
Description: Nonsurgical root canal treatment will be given
Study: NCT02068430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 0.1%
Description: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV-X™ Illumination System
Description: When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
Study: NCT02953392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anorganic Bovine Bone Graft Material
Description: Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anorganic Bovine Bone Graft Material
Description: Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Membrane
Description: Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Membrane
Description: Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shelta Platform Switching Premium Implants
Description: Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
Study: NCT01420393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythm control
Description: Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
Study: NCT03999866

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: airtraq videolaryngoscope
Study: NCT02953392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shelta Platform Switching Premium Implants
Description: Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shelta Platform Matching Premium Implants
Description: Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
Study: NCT03999866

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: airtraq videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: airtraq videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mcgrath mac x-blade
Description: mcgarth mac videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mcgrath mac x-blade
Description: mcgarth mac videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mcgrath mac x-blade
Description: mcgarth mac videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz c-mac
Description: storz c-mac videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz c-mac
Description: storz c-mac videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz c-mac
Description: storz c-mac videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz d-blade
Description: storz d-blade video laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz d-blade
Description: storz d-blade video laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz d-blade
Description: storz d-blade video laryngoscope
Study: NCT00057837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery \> 10,000 dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
Study: NCT02953392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shelta Platform Matching Premium Implants
Description: Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
Study: NCT01111201

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
Study: NCT01693458

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
Description: The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
Description: The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
Study: NCT03965832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNT during exercise
Description: 6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNT during exercise
Description: 6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard oxygen therapy/RA
Description: 6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard oxygen therapy/RA
Description: 6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
Study: NCT01255826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP
Description: After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is \< 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
Study: NCT03713801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
Study: NCT01295047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VERAPAMIL
Description: 240 MG SR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 4 MG
Study: NCT01015950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy'Sup
Description: Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Local food supplement
Description: Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Misola
Description: Locally produced, millet-soy-peanut-based fortified complementary food (Misola)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCSB
Description: Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
Study: NCT00309283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting somatostatin
Description: Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
Study: NCT01255826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.
Description: After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
Study: NCT00309283

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
Study: NCT03005886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal examination
Description: periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal examination
Description: periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periodontal examination
Description: periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements
Study: NCT01156610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment
Description: Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Treatment
Description: Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol).